MedTrace Logo

Single Oral Dose of 60 mg [14C]AZD9668 in Healthy Male Volunteers

NCT01147549 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2010-12-03

No results posted yet for this study

Summary

The purpose of the study is to characterise the absorption, distribution, metabolism and excretion (ADME) of a single oral dose of \[14C\]AZD9668.

Conditions

  • Healthy

Interventions

DRUG

[C14]AZD9668

Oral Solution 60 mg Single Dose

Sponsors & Collaborators

Principal Investigators

  • Chris O'Brien · AstraZeneca R&D, Wilmington

  • Tim Mant, Professor · Quintiles Drug Research Unit, United Kingdom

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01147549 on ClinicalTrials.gov